Orforglipron
-
Orforglipron: Lilly’s Oral GLP-1 Shows Strong Efficacy and Safety in Phase 3 Data Published in NEJM
Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.
